Yu (Emily) Liu

emilyl3@andrew.cmu.edu | (484)-800-6494

OBJECTIVE

Entry-level writing professional with exceptional written communication and storytelling skills, looking to make social and scientific research accessible for all audiences.

EDUCATION

Carnegie Mellon University, Pittsburgh, PA

(Expected) Sep. 2024–Dec. 2025

Master of Arts in Professional Writing

University of Pittsburgh, Pittsburgh, PA

Sep. 2019-Apr. 2023

Bachelor of Science in Biological Sciences

Minor in Creative Writing

SKILLS

Fiction and Nonfiction Writing | Written Communication

Adobe Creative Cloud | Cascade CMS | Microsoft Office Suite

Cell Culture | Biomedical Research

EXPERIENCE

Writing and Communications Intern, Carnegie Mellon University

Feb. 2024-Jul. 2024

- · Wrote/edited feature stories and summaries for a general audience
- · Interviewed College of Engineering faculty, students, and alumni
- · Managed the College of Engineering website through Cascade CMS

Editorial Intern, Pitt Med Magazine, University of Pittsburgh

Jan. 2022-Apr. 2022

- · Researched leads, wrote pitches for future articles, and drafted long features
- · Interviewed Pitt School of Medicine alumni
- Managed the @PittMedMag X/Twitter page

Oncology Translational Research Intern, Johnson & Johnson Innovative Medicine

May 2022-Aug. 2022

- · Applied various in vitro techniques to study acute myeloid leukemia
- · Produced a poster detailing experimental results, and presented the poster at a research symposium
- Drafted and edited a J&J newsletter article about the internship program's closing ceremony

Undergraduate Researcher, University of Pittsburgh

Sep. 2021-Jan. 2023

- · Applied various in vitro techniques to study castration-resistant prostate cancer
- Investigated mechanisms of cell cycle checkpoint kinases, culminating in co-authorship on publications
- · Wrote and edited a report detailing my findings in the format of a research paper

PUBLICATIONS

- Understanding the 3D ice-printing process to create micro-scale structures
- · Alum spotlight: Sebastian L. Vega
- Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer